ERBB2 and neoplasm: T-DXd specifically binds to HER2 and is internalized within tumor cells, where the linker is cleaved by lysosomal enzymes to release deruxtecan, which inhibits topoisomelase I, leading to DNA damage, apoptosis, and inhibition of tumor cell proliferation.